East Midlands Cancer Network Guidelines for diagnosis and management of mature T cell and NK cell lymphomas (excluding cutaneous T cell lymphoma)
|
|
- Meryl Hunt
- 6 years ago
- Views:
Transcription
1 East Midlands Cancer Network Guidelines for diagnosis and management of mature T cell and NK cell lymphomas (excluding cutaneous T cell lymphoma) Written by: Dr Chris Fox with input from Dr Fiona Miall and Dr Andy Haynes Consultation Group EMCN Haematology NSSG Summary Lymphomas of mature T cell and NK cell origin are a group of biologically and clinically heterogeneous malignancies. Most subtypes behave aggressively and resistance to conventional chemotherapy regimens is common. Compared to their B cell counterparts, patients with T/NK lymphoma more often have a poorer performance status at diagnosis, extranodal disease, B symptoms and unfavourable prognostic indices. With the possible exception of Alk-positive anaplastic large cell lymphoma, there is no consensus on the optimal therapy for these diseases and the 5-year survival following CHOP-like regimens is approximately 30% in most studies. Where possible, patients should be enrolled into clinical study protocols. Patients with high-risk disease should be considered for intensive first-line therapy, including autologous and allogeneic stem cell transplant for appropriately selected patients. This guideline excludes the mature T cell leukaemias and the cutaneous T cell lymphomas Diagnosis Expert haematopathological review of tissue biopsies incorporating morphology, immunohistochemistry, flow cytometry and molecular genetic data is essential for accurate diagnosis and sub-classification in particular. Lymph node excision is preferred but core biopsy may be sufficient in some cases or for extra-nodal sites. Fine-needle aspirate per se is insufficient. Correlation with clinical features is critical and re-biopsy may be required in some cases. Staging Standard blood tests should include all routine haematology and biochemistry, serum LDH, immunoglobulins and beta-2 microglobulin. All patients should be tested for HIV, Hepatitis B and C. CMV, EBV and HTLV serology and PCR may be required in selected cases. ECOG performance status should be recorded. IPI should be recorded. Written By: Dr Chris Fox Authorised by: EMCN Haem NSSG Page Number: 1/6
2 Bone marrow aspirate and trephine biopsy is required and has prognostic value. Whole body CT scan with contrast. The vast majority of T-NHLs are FDG-avid and up to 18% of patients may be upstaged as compared to conventional CT[1]. Pre-treatment staging with FDG-PET is recommended (but not mandated) for patients with T-NHL prior to active therapy. Prognosis Applying the IPI (as validated for DLBCL) can effectively stratify T-NHL although a large proportion of cases are assigned an intermediate or high-risk score. A modified IPI for T cell lymphomas provides better separation of risk groups and delineates prognosis based on age, LDH, bone marrow involvement and PS[2]. For specific subtypes such as NK/T lymphoma, the predictive value of a low IPI is particularly poor and more disease-specific scores (NK-IPI) should be applied. Treatment Delivery CHOP or CHOP-like first-line regimens can be delivered at level IIA, salvage therapy or intensive first-line therapy can be delivered at level IIB. Autologous and allogeneic stem cell transplant should be delivered at a JACIE-accredited BMT unit. All patients should be offered the opportunity to participate in an approved clinical trial protocol if available. Recommendations for Therapy FIRST-LINE 1. Systemic Alk-positive Anaplastic Large T cell lymphoma. This subtype should be distinguished from the primary cutaneous entity and from Alknegative disease. a. Stage IA ALK+ALCL with no adverse prognostic features by IPI should be treated with 3-4cycles of CHOP or CHOEP followed by radiotherapy. b. Stage IB-IV should receive 6 cycles of CHOP or CHOEP chemotherapy 2. Extra-nodal NK/T lymphoma (nasal-type) [ENKTL]. This subtype is very rare in the UK. Most cases have an NK genotype/phenotype but approximately 15% have a cytotoxic CD8+ phenotype. EBV-positivity of the tumour as determined by EBER in-situ hybridisation is a requisite for diagnosis. a. Patients with localised disease (IE/IIE) should receive radiation with 50-55Gy. Evidence supports an improved outcome with the use of additional chemotherapy although the optimal regimen has not been examined in a randomised study. High-expression of P-glycoprotein (PGP) by the tumour cells makes anthracycline and vinca alkyloid agents less desirable. Two recent phase II studies examined non- PGP, non-cross resistant chemotherapy regimens (Etoposide/Ifosfamide/Cisplatin/Dexamethasone) either concurrent with or following radiotherapy with very encouraging outcomes[3, 4] and superior to previous studies with radiotherapy-alone or radiotherapy-chop combinations. Such an approach is recommended for stage IE-IIE ENKTL. Other similar regimens such as Written By: Dr Chris Fox Authorised by: EMCN Haem NSSG Page Number: 2/6
3 ESHAP, IVAC or GemP could also be considered. For frailer patients, oral Fludarabine/Cyclophosphamide or CHOP/CHOEP are reasonable options, with the former regimen favoured in view of MDR1/PGP expression. A lack of good data makes formal recommendations difficult in this group of patients; individualised decisions may be required. b. Patients with advanced stage disease, extranasal disease or relapsed/refractory ENKTL have a dismal prognosis with conventional chemotherapy. However, recent data on L-asparaginase-containing regimens such as AspMetDex[5] or the SMILE regimen[6, 7] appear active (Pegylated L-asparaginase is recommended- see Lunning, M et al Blood ASH Annual Meeting Abstracts, Nov 2011; 118: 2688.). Responding patients should be considered for autologous or allogeneic stem cell transplant. 3. Enteropathy-associated T-cell lymphoma. An aggressive tumour of the small bowel usually associated with antecedent coeliac disease. Many patients have a poor performance status and nutritional deficiency at diagnosis. a. CHOP or CHOP-like therapy alone results in long-term survival for <10% patients and although may be appropriate for elderly patients, is not recommended as sole therapy for those fit enough for a more intensive approach (see (b)). However, as in the current NCRI protocol, one cycle of CHOP may be a pragmatic initial choice to improve performance and nutritional status prior to commencing an IVE-based protocol. b. Where possible, patients should be entered into a clinical trial. The current NCRI Phase II study, based on published experience[8, 9], employs an approach based on IVE, high-dose-mtx and consolidated by a BEAM-conditioned autologous stem cell transplant in CR1. Such an intensive approach should be considered for all sufficiently fit patients, preferably within the NCRI study. c. All patients should receive dietetic/nutritional/gastroeneterology support where appropriate and many may require enteral or parenteral feeding concurrent with therapy. 4. Peripheral T cell lymphoma (not otherwise specified) Angioimmunoblastic T cell lymphoma Alk-negative Anaplastic Large T cell lymphoma a. Although no randomised trial has demonstrated superiority of other regimens over CHOP for these poor-prognosis tumours, long-term survival with this approach in most studies does not exceed 30% and early disease progression is common. Patients should be ideally offered participation in a clinical study. b. Where a clinical trial protocol is not available, the following regimens are reasonable to consider as first-line induction therapy in sufficiently fit patients:- i. CHOP or CHOEP (Note disease progression during CHOP/CHOEP is common and early intensification to ii, iii or iv is recommended where possible. CHOEP may improve the quality of response over CHOP and a 14-day cycle is preferred, to enable prompt intensification.) ii. IVE with/without high-dose MTX ( Newcastle protocol ) iii. ESHAP Written By: Dr Chris Fox Authorised by: EMCN Haem NSSG Page Number: 3/6
4 iv. GemP - with/without high-dose MTX. c. Consolidation with autologous HSCT in first CR should be considered for suitable, chemo-sensitive patients[10]. d. For high-risk patients, where long-term survival with conventional therapy may be as low as 10-30%, an allogeneic stem cell transplant should be considered in first response, particularly for those who fail to achieve CR with first-line therapy. No published data exist comparing autologous versus allogeneic SCT in T-NHL and this decision is best made on a patient-by-patient basis, taking into account prognostic features, quality of response to first-line therapy, donor availability, predicted transplant-related mortality and patient s wishes. Good evidence exists for a potent graft-versus-lymphoma effect[11, 12] but a stable remission prior to allograft is critical; chemoresistance is a substantial problem for relapsed T cell lymphoma and a stable second remission may not be achieved. 5. Hepato-splenic gamma-delta T cell lymphoma a. This is an extremely rare, aggressive subtype with a dismal prognosis. No 5 year survivors were recorded in the largest international T cell study to-date (Vose et al). Such patients should be considered for a first-remission allogeneic stem cell transplant as long-term survivors are reported after such an approach. b. There is no robust evidence for a particular chemotherapy regimen but dose- and time-intense non-cross-resistant regimens are favoured; such as CODOX-M/IVAC or other established Ifosphamide-based regimen(s) alternating with Platinum or Methotrexate-based protocols. Interim and end-of treatment imaging Data on the predictive value of interim PET-CT is extremely limited and this should only be undertaken in the context of a clinical trial. End of treatment and pre-sct PET-CT for T-NHL offers improved sensitivity over conventional CT for the detection of residual disease and is recommended. Caution however should be applied to the specificity of FDG-avidity in this context and biopsy-confirmation should be considered before further treatment decisions are made. The minimum standard for end-of-therapy restaging is conventional contrastenhanced CT in which case a repeat CT scan is usually performed 3 months later to clarify remission status. Relapsed/Refractory T-NHL 1. The outcome of relapsed and refractory T-NHL is poor. Re-biopsy should always be performed where feasible and clinical trial options should be considered. 2. Treatment decisions will be influenced by nature of first-line therapy, duration of first-remission and biological fitness/performance status. 3. For patients with an initial remission of >1 year and demonstrable chemosensitivity at relapse (e.g. PET-negative response to first-line salvage therapy), consolidation with autologous-hsct may be considered in CR2. However, the prognosis of relapsed T-NHL is poor and chemo-resistance is common. Allogeneic SCT should be considered for those patients relapsing Written By: Dr Chris Fox Authorised by: EMCN Haem NSSG Page Number: 4/6
5 after autologous SCT or with other high-risk features at relapse; for example a short first remission (<1 year) and/or failing to achieve a CR with first-line salvage regimens. Good evidence exists for a graft-versus T cell lymphoma effect[11, 12] although a stable response is required before proceeding to allo-sct; second-line salvage therapy is required for those not achieving a CR to first-line salvage. Salvage options: IVE ESHAP ICE GemP Mini-BEAM SMILE HD-MTX and/or high-dose cytarabine may also be considered where additional CNS-directed therapy is indicated Brentuximab (for relapsed/refractory ALCL, usage within licence, prior funding approval may be required) Paliative options: Vinblastine with/without Dexamethasone Gemcitabine with/without Dexamethasone Oral cyclophosphamide/corticosteroid (continuous therapy) These agents may also be appropriate as first-line therapy to prolong PFS and improve quality of life for elderly patients ineligible for more intensive therapies. In particular the published data on cyclophosphamide/prednisolone (ref 16) should be considered in this context. Novel agents where accessible, appropriate and funded Novel agents: For refractory disease or patients ineligible for an auto- or allo-sct, a number of novel agents with activity in T-NHL have recently emerged with promising response data and should be considered as therapeutic options either through a clinical trial, compassionate use programs or via CDF funding. Clinical Trials In set-up at NUH: Pralatrexate[14] Romidepsin[15] (or other approved HDAC inhibitors) 1. CHEMO-T (CHOP versus GemP) 2. CHOP versus CHP-Brentuximab (Seattle Genetics commercial study) Written By: Dr Chris Fox Authorised by: EMCN Haem NSSG Page Number: 5/6
6 References 1. Cahu, X., et al., 18F-fluorodeoxyglucose-positron emission tomography before, during and after treatment in mature T/NK lymphomas: a study from the GOELAMS group. Ann Oncol, (3): p Gallamini, A., et al., Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood, (7): p Kim, S.J., et al., Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-Cell Lymphoma: Consortium for Improving Survival of Lymphoma study. J Clin Oncol, (35): p Yamaguchi, M., et al., Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/t-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211. J Clin Oncol, (33): p Jaccard, A., et al., Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study. Blood, (6): p Yamaguchi, M., et al., Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/Tcell lymphoma, nasal type: the NK-Cell Tumor Study Group study. J Clin Oncol, (33): p Yamaguchi, M., et al., Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia. Cancer Sci, (5): p Sieniawski, M., et al., Evaluation of enteropathy-associated T-cell lymphoma comparing standard therapies with a novel regimen including autologous stem cell transplantation. Blood, (18): p Bishton, M.J. and A.P. Haynes, Combination chemotherapy followed by autologous stem cell transplant for enteropathy-associated T cell lymphoma. Br J Haematol, (1): p Dearden, C.E., et al., Guidelines for the management of mature T-cell and NK-cell neoplasms (excluding cutaneous T-cell lymphoma). Br J Haematol, (4): p Kyriakou, C., et al., Allogeneic stem cell transplantation is able to induce longterm remissions in angioimmunoblastic T-cell lymphoma: a retrospective study from the lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol, (24): p Corradini, P., et al., Graft-versus-lymphoma effect in relapsed peripheral T- cell non-hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J Clin Oncol, (11): p Fanale, M.A., et al., A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies. Clin Cancer Res, (1): p O'Connor, O.A., et al., Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol, (9): p Coiffier, B., et al., Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy. J Clin Oncol, Tucci, A. et al., Continuous oral cyclophosphamide and prednisolone as a valuable treatment option for peripheral T cell lymphoma. British Journal of Haematology, 152, Written By: Dr Chris Fox Authorised by: EMCN Haem NSSG Page Number: 6/6
NK/T cell lymphoma Recent advances. Y.L Kwong University Department of Medicine Queen Mary Hospital
NK/T cell lymphoma Recent advances Y.L Kwong University Department of Medicine Queen Mary Hospital Natural killer cell lymphomas NK cell lymphomas are mainly extranodal lymphomas Clinical classification
More informationLancashire and South Cumbria Haematology NSSG Guidelines for Follicular Lymphoma:
1 Lancashire and South Cumbria Haematology NSSG Guidelines for Follicular Lymphoma: 2018-19 1.1 Pretreatment evaluation The following tests should be performed: FBC, U&Es, creat, LFTs, calcium, LDH, Igs/serum
More informationPeripheral T-cell lymphomas (PTCL) Specified and Unspecified. Eric Van Den Neste Cliniques universitaires Saint-Luc Bruxelles
Peripheral T-cell lymphomas (PTCL) Specified and Unspecified Eric Van Den Neste Cliniques universitaires Saint-Luc Bruxelles BHS seminar 12, 07 March 2015 Peripheral T-cell lymphomas (PTCL) Specified and
More informationToday, how many PTCL patients are cured? Steven M. Horwitz M.D. Associate Attending Lymphoma Service Memorial Sloan Kettering Cancer Center
Today, how many PTCL patients are cured? Steven M. Horwitz M.D. Associate Attending Lymphoma Service Memorial Sloan Kettering Cancer Center Today, how many PTCL patients are cured? Some but not as many
More informationChanging the landscape of treatment in Peripheral T-cell Lymphoma
Changing the landscape of treatment in Peripheral T-cell Lymphoma Luis Fayad Associate Professor MD Anderson Cancer Center Department of Lymphoma and Myeloma 1 6 What is peripheral 2008 WHO CLASSIFICATION
More informationRecent diagnostic and therapeutic innovations of T-cell-lymphoma. Prof. Nossrat Firusian, Recklinghausen, Germany
Recent diagnostic and therapeutic innovations of T-cell-lymphoma Prof. Nossrat Firusian, Recklinghausen, Germany NODAL Angioimmunoblastic T-cell Lymphoma Peripheral T-cell-Lymphoma Anaplastic Large-cell-Lymphoma
More informationOutcomes of patients with peripheral T-cell lymphoma in first complete remission: data from three tertiary Asian cancer centers
Tang et al. (2017) 7:653 DOI 10.1038/s41408-017-0030-y CORRESPONDENCE Outcomes of patients with peripheral T-cell lymphoma in first complete remission: data from three tertiary Asian cancer centers Open
More informationPeripheral T-cell lymphoma. Matt Ahearne Clinical Lecturer, Leicester
Peripheral T-cell lymphoma Matt Ahearne Clinical Lecturer, Leicester PTCL Objectives To understand the natural history of PTCL To appreciate the importance of accurate diagnosis of PTCL including recent
More informationRelapsed/Refractory Hodgkin Lymphoma
Relapsed/Refractory Hodgkin Lymphoma Anas Younes, MD Chief, Lymphoma Service Memorial Sloan-Kettering Cancer Center New York, New York, United States Case Study 32-year-old woman was diagnosed with stage
More informationWhat is the best approach to the initial therapy of PTCL? standards of treatment? Should all
What is the best approach to the initial therapy of PTCL? standards of treatment? hould all Jia Ruan, M.D., Ph.D. Center for Lymphoma and Myeloma Weill Cornell Medical College New York Presbyterian Hospital
More informationPeripheral T-Cell Lymphoma. Pro auto. Peter Reimer. Klinik für Hämatologie / intern. Onkologie und Stammzelltransplantation
Peripheral T-Cell Lymphoma Pro auto Peter Reimer Klinik für Hämatologie / intern. Onkologie und Stammzelltransplantation Kliniken Essen Süd, Evang. Krankenhaus Essen-Werden ggmbh COSTEM, Berlin 09.09.2011
More informationAggressive Lymphomas - Current. Dr Kevin Imrie Physician-in-Chief, Sunnybrook Health Sciences Centre
Aggressive Lymphomas - Current Dr Kevin Imrie Physician-in-Chief, Sunnybrook Health Sciences Centre Conflicts of interest I have no conflicts of interest to declare Outline What does aggressive lymphoma
More informationUpdate: Non-Hodgkin s Lymphoma
2008 Update: Non-Hodgkin s Lymphoma ICML 2008: Update on non-hodgkin s lymphoma Diffuse Large B-cell Lymphoma Improved outcome of elderly patients with poor-prognosis diffuse large B-cell lymphoma (DLBCL)
More informationAggressive NHL and Hodgkin Lymphoma. Dr. Carolyn Faught November 10, 2017
Aggressive NHL and Hodgkin Lymphoma Dr. Carolyn Faught November 10, 2017 What does aggressive mean? Shorter duration of symptoms Generally need treatment at time of diagnosis Immediate, few days, few weeks
More informationNK/T cell lymphoma Hong Kong Experience with L-Asparaginase containing regimens. Y.L. Kwong University Department of Medicine Queen Mary Hospital
NK/T cell lymphoma Hong Kong Experience with L-Asparaginase containing regimens Y.L. Kwong University Department of Medicine Queen Mary Hospital Management of NK cell malignancies Principles 1. Accurate
More informationExtranodal natural killer/t-cell lymphoma with long-term survival and repeated relapses: does it indicate the presence of indolent subtype?
VOLUME 47 ㆍ NUMBER 3 ㆍ September 2012 THE KOREAN JOURNAL OF HEMATOLOGY ORIGINAL ARTICLE Extranodal natural killer/t-cell lymphoma with long-term survival and repeated relapses: does it indicate the presence
More informationPET-CT in Peripheral T-cell Lymphoma: To Be or Not To Be
PET-CT in Peripheral T-cell Lymphoma: To Be or Not To Be Bruce D. Cheson, M.D. Georgetown University Hospital Lombardi Comprehensive Cancer Center Washington, DC, USA So What is the Question(s)? What is
More informationTreatment outcomes of IMEP as a front-line chemotherapy for patients with peripheral T-cell lymphomas
BLOOD RESEARCH VOLUME 51 ㆍ NUMBER 3 September 2016 ORIGINAL ARTICLE Treatment outcomes of IMEP as a front-line chemotherapy for patients with peripheral T-cell lymphomas Ji Young Lee 1, Sang Min Lee 1,
More informationT-cell Lymphomas Biology and Management
T-cell Lymphomas Biology and Management March-27-2017 Outline Epidemiology Initial Work-up International Prognostic Index Treatment of Diffuse Large B-cell Lymphoma: -Limited Stage -Advanced Stage Frontline:
More informationDr. A. Van Hoof Hematology A.Z. St.Jan, Brugge. ASH 2012 Atlanta
Dr. A. Van Hoof Hematology A.Z. St.Jan, Brugge ASH 2012 Atlanta DLBCL How to improve on R-CHOP What at relapse Mantle cell lymphoma Do we cure patients Treatment at relapse Follicular lymphoma Watch and
More informationOriginal Study. Abstract
Original Study Management of Advanced and Relapsed/ Refractory Extranodal Natural Killer T-Cell Lymphoma: An Analysis of Stem Cell Transplantation and Chemotherapy Outcomes Jonathan E. Brammer, 1 Dai Chihara,
More informationAcute Lymphoblastic Leukemia (ALL) Ryan Mattison, MD University of Wisconsin March 2, 2010
Acute Lymphoblastic Leukemia (ALL) Ryan Mattison, MD University of Wisconsin March 2, 2010 ALL Epidemiology 20% of new acute leukemia cases in adults 5200 new cases in 2007 Most are de novo Therapy-related
More informationUpdates in T cell Lymphoma
Winship Cancer Institute of Emory University Updates in T cell Lymphoma Mary Jo Lechowicz August 2014 Objectives Update current care for patients with Peripheral T cell Non Hodgkin lymphomas (PTCL) upfront
More informationNICE guideline Published: 20 July 2016 nice.org.uk/guidance/ng52
Non-Hodgkin s lymphoma: diagnosis and management NICE guideline Published: 20 July 2016 nice.org.uk/guidance/ng52 NICE 2017. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationReview Article Extranodal Natural-Killer/T-Cell Lymphoma, Nasal Type
Hindawi Publishing Corporation Advances in Hematology Volume 2010, Article ID 627401, 5 pages doi:10.1155/2010/627401 Review Article Extranodal Natural-Killer/T-Cell Lymphoma, Nasal Type Harinder Gill,
More informationPrognostic Factors for PTCL. Julie M. Vose, M.D., M.B.A. University of Nebraska Medical Center
Prognostic Factors for PTCL Julie M. Vose, M.D., M.B.A. University of Nebraska Medical Center jmvose@unmc.edu Distribution of 1314 Cases by Consensus Diagnosis International T-Cell Lymphoma Project Vose
More informationAHSCT in Hodgkin lymphoma - indication and challenges. Bastian von Tresckow German Hodgkin Study Group Cologne University Hospital
AHSCT in Hodgkin lymphoma - indication and challenges Bastian von Tresckow German Hodgkin Study Group Cologne University Hospital AHSCT in Hodgkin Lymphoma The role of AHSCT in HL Mobilisation failure
More informationNON-HODGKIN LYMPHOMA TREATMENT REGIMENS: Peripheral T-Cell Lymphoma (Part 1 of 5)
Peripheral T-Cell Lymphoma (Part 1 of 5) Clinical Trials: The National Comprehensive Cancer Network recommends cancer patient participation in clinical trials as the gold standard for treatment. Cancer
More informationStrategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL
New Evidence reports on presentations given at ASH 2009 Strategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL From ASH 2009: Non-Hodgkin
More informationNon-Hodgkin lymphoma
Non-Hodgkin lymphoma Non-Hodgkin s lymphoma Definition: - clonal tumours of mature and immature B cells, T cells or NK cells - highly heterogeneous, both histologically and clinically Non-Hodgkin lymphoma
More informationCorporate Medical Policy
Corporate Medical Policy Hematopoietic Stem-Cell Transplant for Non-Hodgkin Lymphomas File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplant_for_non_hodgkin_lymphomas
More information2012 by American Society of Hematology
2012 by American Society of Hematology Common Types of HIV-Associated Lymphomas DLBCL includes primary CNS lymphoma (PCNSL) Burkitt Lymphoma HIV-positive patients have a 60-200 fold increased incidence
More informationChange Summary - Form 2018 (R3) 1 of 12
Summary - Form 2018 (R3) 1 of 12 Form Question Number (r3) Type Description New Text Previous Text Today's date was removed 2018 N/A Today's Date Removed from Key Fields 2018 N/A HCT Type 2018 N/A Product
More informationDr Sneha Shah Tata Memorial Hospital, Mumbai.
Dr Sneha Shah Tata Memorial Hospital, Mumbai. Topics covered Lymphomas including Burkitts Pediatric solid tumors (non CNS) Musculoskeletal Ewings & osteosarcoma. Neuroblastomas Nasopharyngeal carcinomas
More informationHematopoietic Stem-Cell Transplantation for Non-Hodgkin Lymphomas. Original Policy Date
MP 7.03.13 Hematopoietic Stem-Cell Transplantation for Non-Hodgkin Lymphomas Medical Policy Section Therapy Issue 12/2013 Original Policy Date 12/2013 Last Review Status/Date Reviewed with literature search/12/2013
More informationControversies and Approaches to T cell Lymphoma Therapy in 2016
Controversies and Approaches to T cell Lymphoma Therapy in 2016 Steven M. Horwitz M.D. Associate Attending Lymphoma Service Memorial Sloan Kettering Cancer Center Associate Professor of Medicine Weill
More informationDiagnosis and patient pathway in lymphomas
The Royal Marsden Diagnosis and patient pathway in lymphomas Dr Ian Chau Consultant Medical Oncologist The Royal Marsden Hospital London & Surrey Change Presentation title and date in Footer dd.mm.yyyy
More informationHODGKIN LYMPHOMA Updated February 2016 by Dr. Manna (PGY 5 Hematology Resident, University of Calgary)
HODGKIN LYMPHOMA Updated February 2016 by Dr. Manna (PGY 5 Hematology Resident, University of Calgary) Reviewed by Dr. Michelle Geddes (Staff Hematologist, University of Calgary) and Dr. Matt Cheung (Staff
More informationImmune checkpoint inhibitors in lymphoma. Catherine Hildyard Haematology Senior Registrar Oxford University Hospitals NHS Foundation Trust
Immune checkpoint inhibitors in lymphoma Catherine Hildyard Haematology Senior Registrar Oxford University Hospitals NHS Foundation Trust Aims How immune checkpoint inhibitors work Success of immune checkpoint
More informationNCCN Non Hodgkin s Lymphomas Guidelines V Update Meeting 06/14/12 and 06/15/12
NCCN Non Hodgkin s Lymphomas Guidelines V.1.213 Update Meeting 6/14/12 and 6/15/12 Guidelines Page and Request Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma (CLL/SLL) Panel Discussion References
More informationCurrent treatment approaches for NK/T-cell lymphoma
Journal of clinical and experimental hematopathology Vol. 57 No.2, XXX-XXX, 2017 JC lin EH xp ematopathol Review Article Current treatment approaches for NK/T-cell lymphoma Motoko Yamaguchi, Kana Miyazaki
More informationPET-imaging: when can it be used to direct lymphoma treatment?
PET-imaging: when can it be used to direct lymphoma treatment? Luca Ceriani Nuclear Medicine and PET-CT centre Oncology Institute of Southern Switzerland Bellinzona Disclosure slide I declare no conflict
More informationSandwich Chemotherapy (CT) with Radiotherapy (RT) Improves Outcomes in Patients with Stage I E. Extranodal Natural Killer (NK)/T-cell Lymphomas
DOI:http://dx.doi.org/10.7314/APJCP.2013.14.7.4061 Sandwich Chemotherapy with Radiotherapy Improves Outcomes with Stage I E /II (NK)/T-cell Lymphomas RESEARCH ARTICLE Sandwich Chemotherapy (CT) with Radiotherapy
More informationPET-adapted therapies in the management of younger patients (age 60) with classical Hodgkin lymphoma
PET-adapted therapies in the management of younger patients (age 60) with classical Hodgkin lymphoma Ryan Lynch MD Assistant Professor, University of Washington Assistant Member, Fred Hutchinson Cancer
More informationISSN: (Print) (Online) Journal homepage:
Hematology ISSN: (Print) 1607-8454 (Online) Journal homepage: https://www.tandfonline.com/loi/yhem20 Effectiveness of pegaspargase, gemcitabine, and oxaliplatin (P-GEMOX) chemotherapy combined with radiotherapy
More informationCorporate Medical Policy
Corporate Medical Policy Hematopoietic Stem-Cell Transplantation in the Treatment of Germ File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplantation_in_the_treatment_of_germ_cell_tumor
More informationNON HODGKINS LYMPHOMA: INDOLENT Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary)
NON HODGKINS LYMPHOMA: INDOLENT Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary) Reviewed by Dr. Michelle Geddes (Staff Hematologist, University of Calgary) and Dr.
More informationNavigating Treatment Pathways in Relapsed/Refractory Hodgkin Lymphoma
Welcome to Managing Hodgkin Lymphoma. I am Dr. John Sweetenham from Huntsman Cancer Institute at the University of Utah. In today s presentation, I will be discussing navigating treatment pathways in relapsed
More informationLugano classification: Role of PET-CT in lymphoma follow-up
CAR Educational Exhibit: ID 084 Lugano classification: Role of PET-CT in lymphoma follow-up Charles Nhan 4 Kevin Lian MD Charlotte J. Yong-Hing MD FRCPC Pete Tonseth 3 MD FRCPC Department of Diagnostic
More informationIs there a Role for Upfront Stem Cell Transplantation in Peripheral T-Cell Lymphoma: YES!
Is there a Role for Upfront Stem ell Transplantation in Peripheral T-ell Lymphoma: YES! Norbert Schmitz Dep. Hematology, Oncology and Stem ell Transplantation AK St. Georg Hamburg, Germany OS in the common
More informationORIGINAL ARTICLE CHARACTERISTICS AND OUTCOMES OF ANAPLASTIC LARGE CELL LYMPHOMA PATIENTS-A SINGLE CENTRE EXPERIENCE
ORIGINAL ARTICLE CHARACTERISTICS AND OUTCOMES OF ANAPLASTIC LARGE CELL LYMPHOMA PATIENTS-A SINGLE CENTRE EXPERIENCE Sohail Athar, Neelam Siddiqui, Abdul Hameed Department of Medical Oncology, Shaukat Khanum
More information1. Please review the following table, make any changes you think are necessary and highlight those changes. Feel free to put notes on the next page
COME HOME Non-Hodgkin pathway development worksheet, v6 September 2014 1. Please review the following table, make any changes you think are necessary and highlight those changes. Feel free to put notes
More informationThey are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:
bring together everything NICE says on a topic in an interactive flowchart. are interactive and designed to be used online. They are updated regularly as new NICE guidance is published. To view the latest
More informationKamakshi V Rao, PharmD, BCOP, FASHP University of North Carolina Medical Center UPDATE IN REFRACTORY HODGKIN LYMPHOMA
Kamakshi V Rao, PharmD, BCOP, FASHP University of North Carolina Medical Center UPDATE IN REFRACTORY HODGKIN LYMPHOMA Objectives Describe the current standard approach for patients with relapsed/refractory
More informationEBMT2008_22_44:EBMT :29 Pagina 454 CHAPTER 30. HSCT for Hodgkin s lymphoma in adults. A. Sureda
EBMT2008_22_44:EBMT2008 6-11-2008 9:29 Pagina 454 * CHAPTER 30 HSCT for Hodgkin s lymphoma in adults A. Sureda EBMT2008_22_44:EBMT2008 6-11-2008 9:29 Pagina 455 CHAPTER 30 HL in adults 1. Introduction
More informationTRANSPARENCY COMMITTEE OPINION. 27 January 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 27 January 2010 TORISEL 25 mg/ml, concentrate for solution and diluent for solution for infusion Box containing 1
More informationBLOOD RESEARCH REVIEW ARTICLE THE HISTORY OF KLWP-CISL INTRODUCTION
BLOOD RESEARCH VOLUME 48 ㆍ NUMBER 3 September 2013 REVIEW ARTICLE Review of the clinical research conducted by the Consortium for Improving Survival of Lymphoma of the Korean Society of Hematology Lymphoma
More informationIndolent Lymphomas. Dr. Melissa Toupin The Ottawa Hospital
Indolent Lymphomas Dr. Melissa Toupin The Ottawa Hospital What does indolent mean? Slow growth Often asymptomatic Chronic disease with periods of relapse (long natural history possible) Incurable with
More informationA Phase II Clinical Trial of Fludarabine and Cyclophosphamide Followed by. Thalidomide for Angioimmunoblastic T-cell Lymphoma. An NCRI Clinical Trial.
A Phase II Clinical Trial of Fludarabine and Cyclophosphamide Followed by Thalidomide for Angioimmunoblastic T-cell Lymphoma. An NCRI Clinical Trial. CRUK number C17050/A5320 William Townsend 1, Rod J
More informationAngioimmunoblastic T-cell lymphoma: nobody knows what to do...
Angioimmunoblastic T-cell lymphoma: nobody knows what to do... Felicitas Hitz, Onkologie/Hämatologie St.Gallen SAMO Lucerne 17.9.2011 : Problems PTCL are rare diseases with even rarer subgroups Difficulte
More informationbrentuximab vedotin (Adcetris ) 50mg powder for concentrate for solution for infusion SMC No. (845/12) Takeda UK Ltd
brentuximab vedotin (Adcetris ) 50mg powder for concentrate for solution for infusion SMC No. (845/12) Takeda UK Ltd 05 September 2014 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationPeripheral T-Cell Lymphoma: A Case-Based Discussion of Recent Advances in Patient Management
A p r i l 2 0 1 1 w w w. c l i n i c a l a d v a n c e s. c o m V o l u m e 9, I s s u e 4, S u p p l e m e n t 9 Discussants Carlos M. Franco, MD Georgia Cancer Specialists Atlanta, Georgia Leslie L.
More informationBelinostat (Beleodaq) with CHOP for treatment of patients with peripheral T cell lymphoma, 1st line
NIHR Innovation Observatory Evidence Briefing: September 2017 Belinostat (Beleodaq) with CHOP for treatment of patients with peripheral T cell lymphoma, 1st line NIHRIO (HSRIC) ID: 12674 NICE ID: 9532
More informationbefore, during and after treatment in mature T/NK lymphomas: a study from the GOELAMS group
Annals of Oncology 22: 705 711, 2011 doi:10.1093/annonc/mdq415 Published online 25 August 2010 18 F-fluorodeoxyglucose positron emission tomography before, during and after treatment in mature T/NK lymphomas:
More informationThe treatment of DLBCL. Michele Ghielmini Medical Oncology Dept Oncology Institute of Southern Switzerland Bellinzona
The treatment of DLBCL Michele Ghielmini Medical Oncology Dept Oncology Institute of Southern Switzerland Bellinzona NHL frequency at the IOSI Mantle Cell Lymphoma 6.5 % Diffuse Large B-cell Lymphoma 37%
More informationPeripheral T-cell lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
clinical practice guidelines Annals of Oncology 26 (Supplement 5): v108 v115, 2015 doi:10.1093/annonc/mdv201 Peripheral T-cell lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and
More informationRecent Advances in the Treatment of Peripheral T-Cell Lymphoma
Hematologic Malignancies Recent Advances in the Treatment of Peripheral T-Cell Lymphoma KAMEL LARIBI, a MUSTAPHA ALANI, a CATHERINE TRUONG, b ALIX BAUGIER DE MATERRE c a Department of Hematology, Centre
More informationPREHYDRATION: 1000 ml NS with potassium chloride 20 meq and magnesium sulphate 2 g IV over 1 hour prior to CISplatin
BC Cancer Protocol Summary for Treatment of Newly Diagnosed Nasal, Extranodal Natural Killer (NK) or T-cell lymphoma, using Concurrent Radiation and weekly CISplatin followed by Etoposide, Ifosfamide,
More informationTCH em Linfomas T. Fábio R. Kerbauy
TCH em Linfomas T Fábio R. Kerbauy T-Cell Lymphomas ( 6000 cases/y USA) J Clin Oncol 2008;26:4124-4130 Proportion T-cell lymphomas prognosis by subtipe 1.0 0.9 0.8 0.7 0.6 0.5 ALCL ALK+ 0.4 0.3 0.2 0.1
More informationWhat are the hurdles to using cell of origin in classification to treat DLBCL?
What are the hurdles to using cell of origin in classification to treat DLBCL? John P. Leonard, M.D. Richard T. Silver Distinguished Professor of Hematology and Medical Oncology Associate Dean for Clinical
More informationLarge cell immunoblastic Diffuse histiocytic (DHL) Lymphoblastic lymphoma Diffuse lymphoblastic Small non cleaved cell Burkitt s Non- Burkitt s
Non Hodgkin s Lymphoma Introduction 6th most common cause of cancer death in United States. Increasing in incidence and mortality. Since 1970, the incidence of has almost doubled. Overview The types of
More informationPolicy for Central Nervous System [CNS] Prophylaxis in Lymphoid Malignancies
Policy for Central Nervous System [CNS] Prophylaxis in Lymphoid Malignancies UNCONTROLLED WHEN PRINTED Note: NOSCAN Haematology MCN has approved the information contained within this document to guide
More informationLymphoma: The Basics. Dr. Douglas Stewart
Lymphoma: The Basics Dr. Douglas Stewart Objectives What is lymphoma? How common is it? Why does it occur? How do you diagnose it? How do you manage it? How do you follow patients after treatment? What
More informationExtranodal natural killer T-cell lymphoma, nasal type, presenting as periorbital cellulitis: A case report
CASE REPORT Miller et al. 1 PEER REVIEWED OPEN ACCESS Extranodal natural killer T-cell lymphoma, nasal type, presenting as periorbital cellulitis: A case report Katherine Miller, Amir Kamran, Anna Koget
More informationHematopoietic Stem-Cell Transplantation for Non-Hodgkin s Lymphomas
Hematopoietic Stem-Cell Transplantation for Non-Hodgkin s Lymphomas Policy Number: 8.01.20 Last Review: 7/2014 Origination: 7/2002 Next Review: 7/2015 Policy Blue Cross and Blue Shield of Kansas City (Blue
More informationStandard Regimens for Haematology
Regimens for Haematology ChlVPP Chlorambucil 6mg/m 2 PO D1 to 14 Vinblastine 6mg/m 2 (max 10mg) IV on D1 & 8 Procarbazine 100mg/m 2 PO on D1 to 14 Prednisolone 40mg PO D1 to 14 ABVD Doxorubicin 25mg/m
More informationAppendix 6: Indications for adult allogeneic bone marrow transplant in New Zealand
Appendix 6: Indications for adult allogeneic bone marrow transplant in New Zealand This list provides indications for the majority of adult BMTs that are performed in New Zealand. A small number of BMTs
More informationNON HODGKINS LYMPHOMA: AGGRESSIVE Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary)
NON HODGKINS LYMPHOMA: AGGRESSIVE Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary) Reviewed by Dr. Michelle Geddes (Staff Hematologist, University of Calgary) and
More informationDisclosures WOJCIECH JURCZAK
Disclosures WOJCIECH JURCZAK ABBVIE (RESEARCH FUNDING), CELGENE (RESEARCH FUNDING); EISAI (RESEARCH FUNDING); GILEAD (RESEARCH FUNDING); JANSEN (RESEARCH FUNDING); MORPHOSYS (RESEARCH FUNDING), MUNDIPHARMA
More informationCAR-T cell therapy pros and cons
CAR-T cell therapy pros and cons Stephen J. Schuster, MD Professor of Medicine Perelman School of Medicine of the University of Pennsylvania Director, Lymphoma Program & Lymphoma Translational Research
More informationThey are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:
bring together everything NICE says on a topic in an interactive flowchart. are interactive and designed to be used online. They are updated regularly as new NICE guidance is published. To view the latest
More informationAlexander Fosså, M.D. PhD.
Alexander Fosså, M.D. PhD. Current position: Senior Consultant, Department of Medical Oncology Oslo University Hospital Focus of work: - Malignant lymphoma - Chemotherapy, immunotherapy, radiotherapy -
More informationPoteligeo (mogamulizmuab-kpkc)
Poteligeo (mogamulizmuab-kpkc) Policy Number: 5.02.556 Last Review: 1/2019 Origination: 1/2019 Next Review: 1/2020 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Poteligeo
More informationLinfoma de Hodgkin. Novos medicamentos. Otavio Baiocchi CRM-SP
Linfoma de Hodgkin Novos medicamentos Otavio Baiocchi CRM-SP 96.074 Hodgkin Lymphoma Unique B-cell lymphoma HRS malignant cells Scattered malignant Hodgkin-Reed-Sternberg (RS) cells in a background of
More informationHematopoietic Cell Transplantation for Non-Hodgkin's Lymphomas
Medical Policy Manual Transplant, Policy No. 45.23 Hematopoietic Cell Transplantation for Non-Hodgkin's Lymphomas Next Review: September 2018 Last Review: December 2017 Effective: January 1, 2018 IMPORTANT
More informationA.M.W. van Marion. H.M. Lokhorst. N.W.C.J. van de Donk. J.G. van den Tweel. Histopathology 2002, 41 (suppl 2):77-92 (modified)
chapter 4 The significance of monoclonal plasma cells in the bone marrow biopsies of patients with multiple myeloma following allogeneic or autologous stem cell transplantation A.M.W. van Marion H.M. Lokhorst
More informationRadiotherapy in DLCL is often worthwhile. Dr. Joachim Yahalom Memorial Sloan-Kettering, New York
Radiotherapy in DLCL is often worthwhile Dr. Joachim Yahalom Memorial Sloan-Kettering, New York The case for radiotherapy Past: Pre-Rituximab randomized trials Present: R-CHOP as backbone, retrospective
More informationPractical Application of PET adapted Therapy in Hodgkin Lymphoma
Practical Application of PET adapted Therapy in Hodgkin Lymphoma Matthew Matasar, MD Lymphoma and Adult BMT Services Director, Lymphoma Survivorship Clinic Memorial Sloan Kettering Cancer Center New York,
More informationLYMPHOMA Joginder Singh, MD Medical Oncologist, Mercy Cancer Center
LYMPHOMA Joginder Singh, MD Medical Oncologist, Mercy Cancer Center Lymphoma is cancer of the lymphatic system. The lymphatic system is made up of organs all over the body that make up and store cells
More informationLymphomas and multiple myeloma 12/23/2018 1
60 Lymphomas and multiple myeloma 12/23/2018 1 Lymphomas Lymphoma is cancer of the lymphatic system. Lymphomas are subdivided into two main categories: Hodgkin's lymphoma (HL) and non- Hodgkin's lymphoma
More information2.07 Protocol Name: CHOP & Rituximab
2.07 Protocol Name: CHOP & Rituximab Indication Intermediate and high grade, B-cell non-hodgkins lymphoma expressing CD20. Second or third line therapy for low grade, B cell non- Hodgkins lymphoma expressing
More informationNon-Hodgkin s Lymphoma
Non-Hodgkin s Lympoma Non-Hodgkin s Lymphomas Janet H. Van Cleave MSN, ACNP-CS, CS, AOCN Acute Care Nurse Practitioner The Mount Sinai Medical Center of New York City Doctoral Student, Yale University
More informationDr Claire Burney, Lymphoma Clinical Fellow, Bristol Haematology and Oncology Centre, UK
EMBT LWP 2017-R-05 Research Protocol: Outcomes of patients treated with Ibrutinib post autologous stem cell transplant for mantle cell lymphoma. A retrospective analysis of the LWP-EBMT registry. Principle
More informationDiffuse Large B-Cell Lymphoma (DLBCL)
Diffuse Large B-Cell Lymphoma (DLBCL) DLBCL/MCL Dr. Anthea Peters, MD, FRCPC University of Alberta/Cross Cancer Institute Disclosures Honoraria from Janssen, Abbvie, Roche, Lundbeck, Seattle Genetics Objectives
More informationB Cell Lymphoma: Aggressive
B Cell Lymphoma: Aggressive UpToDate: Introduction: Risk Factors: Biology: Symptoms: Diagnosis: Ibrutinib approved for mantle cell lymphoma as 2nd line therapy. - Aggressive lymphomas are a group of malignant
More informationHematopoietic Stem-Cell Transplantation for Non-Hodgkin Lymphomas
Hematopoietic Stem-Cell Transplantation for Non-Hodgkin Lymphomas Policy Number: Original Effective Date: MM.07.018 04/01/2008 Line(s) of Business: Current Effective Date: HMO; PPO 03/27/2015 Section:
More informationInterim PET in Diffuse Large B Cell Lymphoma.The GEL/TAMO experience
Interim PET in Diffuse Large B Cell Lymphoma.The GEL/TAMO experience MD. Caballero, Hospital Universitario, Salamanca, Spain. Chair of The GEL/TAMO Group Menton,9 april 2010 Disclosures for Dolores Caballero
More informationGa-67 scintigraphy in lymphoma patients undergoing bone marrow transplantation
54 Turkish Journal of Cancer Volume 37, No. 2, 27 Ga-67 scintigraphy in lymphoma patients undergoing bone marrow transplantation PINR ÖZGEN KIRTLI 1, ELKIS ERŞ 1, EVREN ÖZDEMİR 2, YENER KOÇ 3 Hacettepe
More informationpan-canadian Oncology Drug Review Initial Clinical Guidance Report Pralatrexate (Folotyn) for Peripheral T-cell Lymphoma
pan-canadian Oncology Drug Review Initial Clinical Guidance Report Pralatrexate (Folotyn) for Peripheral T-cell Lymphoma January 31, 2019 DISCLAIMER Not a Substitute for Professional Advice This report
More informationWhat s a Transplant? What s not?
What s a Transplant? What s not? How to report the difference? Daniel Weisdorf MD University of Minnesota Anti-cancer effects of BMT or PBSCT [HSCT] Kill the cancer Save the patient Restore immunocompetence
More information